Most genes produce multiple non-coding and coding RNA transcripts with potentially divergent biological functions, yet their contribution to cancer remains largely unexplored. Here, we built an integrated, transcript-resolution RNA-sequencing atlas of prostate cancer spanning 1,140 clinical samples from 10 independent...
Ji-Chang Zhang, Claudio Lorenzi, D. Bossi et al.· bioRxiv· 0 citations
The feasibility and efficacy of this novel mini-body-based strategy as a viable therapeutic modality for targeting an oncogenic transcription factor previously considered undruggable are established and supports further translational development for targeting ERG-driven prostate cancer.
C. Musumeci, Concetta Guerra, D. Albino et al.· Clinical Cancer Research· 0 citations
WI23-B is highlighted as a promising lead peptide with potent WWP1 inhibitory activity and synergistic antiproliferative effects when combined with PI3K inhibitors, and has the potential to reshape therapeutic strategies for BC and TNBC by enabling more effective and less toxic treatment regimens.
E. M. A. Fassi, Sara Mathlouthi, E. Maspero et al.· bioRxiv· 0 citations
It is shown that plasma IgG reactivity to this region remains rare, even after repeated antigen exposure, and kinetic and avidity constraints governing neutralization at the HR2 stem helix and position hr2.016 as a resilient therapeutic candidate.
Virginia Crivelli, Concetta Guerra, M. Abernathy et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
